Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Matsukiyo Cocokara & Co. is Japan's largest drugstore chain operator with over 1,700 retail locations across the country, combining pharmacy services with health/beauty products, cosmetics, and daily necessities. The company benefits from Japan's aging demographics driving pharmaceutical demand while capturing tourist spending through tax-free shopping programs. Stock performance is driven by same-store sales growth, store expansion economics, and inbound tourism recovery post-pandemic.
Operates high-traffic retail locations with pharmacy services as anchor tenant, generating foot traffic for higher-margin health/beauty products. Pricing power comes from private label brands (estimated 15-20% of sales), pharmacy services requiring licensed pharmacists creating barriers to entry, and tourist tax-free shopping programs generating incremental high-margin sales. Gross margin of 35.1% reflects mix of lower-margin pharmaceuticals offset by higher-margin cosmetics/beauty products. Operating leverage comes from spreading fixed store costs across growing same-store sales and leveraging centralized distribution infrastructure across 1,700+ locations.
Same-store sales growth rates (comp store sales), particularly in existing mature locations
Inbound tourist spending and tax-free sales volumes, heavily influenced by Chinese visitor traffic
New store opening pace and unit economics (target 50-80 new stores annually)
Private label brand penetration rates and gross margin expansion initiatives
Pharmacy prescription volume growth driven by Japan's aging population demographics
Japan's declining and aging population creating long-term headwinds for retail traffic growth, though offset partially by increased per-capita healthcare spending
E-commerce competition from Amazon Japan, Rakuten, and specialized online pharmacies eroding foot traffic for non-pharmacy categories
Regulatory changes to pharmaceutical pricing and reimbursement rates under Japan's national health insurance system potentially compressing pharmacy margins
Shift toward online prescription fulfillment and telemedicine reducing in-store pharmacy visits
Intense competition from other major drugstore chains (Welcia Holdings, Sugi Holdings, Tsuruha Holdings) in key metropolitan markets driving promotional activity
Convenience store chains (7-Eleven, Lawson, FamilyMart) expanding health/beauty assortments and encroaching on drugstore categories
Discount retailers and category specialists (Don Quijote, Tokyu Hands) competing on price for non-pharmacy merchandise
Minimal financial risk given zero debt and strong cash generation, though high capex requirements (¥14.5B annually) for store expansion could pressure free cash flow if same-store sales deteriorate
Working capital intensity from inventory management across 1,700+ locations requiring efficient supply chain execution to avoid obsolescence in beauty/cosmetics categories
low-to-moderate - Pharmaceutical sales are non-discretionary and resilient through economic cycles, supported by Japan's national health insurance system. However, health/beauty and discretionary product categories (35-40% of sales) show moderate sensitivity to consumer confidence and disposable income. Inbound tourism component adds cyclical exposure to regional economic conditions and currency fluctuations affecting travel demand.
Low direct sensitivity given zero debt on balance sheet (0.00 D/E ratio). However, rising Japanese interest rates could marginally impact consumer discretionary spending on non-essential health/beauty products. Store expansion capex is funded from operating cash flow rather than debt financing, insulating from rate volatility. Valuation multiples may compress if Japanese government bond yields rise significantly, making growth stocks less attractive.
Minimal - Company operates with no net debt and strong current ratio of 2.24x, indicating robust liquidity. Business model generates consistent operating cash flow of ¥81.5B with minimal credit risk exposure. Customer transactions are predominantly cash/card-based retail with no meaningful accounts receivable risk.
value - Trading at 0.9x Price/Sales and 8.3x EV/EBITDA with 926.8% FCF yield (likely data anomaly, but indicates strong cash generation), the stock attracts value investors seeking stable cash flows from Japan's defensive retail sector. Modest 3.8% revenue growth and 10.9% ROE appeal to investors prioritizing capital efficiency and shareholder returns over high growth. Recent 14.3% decline over six months may attract contrarian value investors betting on tourism recovery.
low-to-moderate - As a large-cap Japanese retail staple with defensive pharmaceutical exposure, the stock exhibits lower volatility than broader Japanese equity markets. However, sensitivity to tourism flows and yen exchange rate fluctuations introduces moderate volatility during periods of currency stress or geopolitical tensions affecting regional travel.
